Browsing Tag
Ulcerative colitis
32 posts
Abivax (NASDAQ: ABVX) obefazimod NDA path meets a safety debate the market is still pricing
Abivax (NASDAQ: ABVX) put up Rinvoq-like ulcerative colitis remission data and dropped 40 percent. The question is whether the malignancy debate sticks.
Accro Bioscience raises $50m Series C to advance AC-101 and immune-mediated disease pipeline
Ulcerative colitis needs safer oral options. Accro’s OrbiMed-led raise puts RIPK2 inhibition under a bigger clinical spotlight.
Innovent Biologics achieves key milestone as PECONDLE delivers sustained efficacy in Phase 3 psoriasis trial
Find out how Innovent’s PECONDLE is redefining long-term psoriasis care with sustained response and quarterly dosing.
Abivax delivers breakthrough Phase 3 data: obefazimod improves quality of life in moderate-to-severe ulcerative colitis
Discover how Abivax’s obefazimod improved quality of life and achieved remission in Phase 3 ulcerative colitis trials—see why experts call it a game changer.
AbbVie wins FDA nod expanding RINVOQ label to Crohn’s disease in major IBD market milestone
Find out how AbbVie’s FDA approval for RINVOQ in Crohn’s disease is reshaping IBD therapy and boosting investor confidence in its post-Humira strategy.
Can AbbVie’s RINVOQ fill the biologics gap for IBD patients unsuitable for TNF therapy?
AbbVie gets FDA approval for broader RINVOQ use in IBD patients beyond TNF blockers. Find out how this impacts stock sentiment and investor expectations.
Can Protagonist’s icotrokinra become the first oral IL-23 therapy to rival biologics in ulcerative colitis?
Positive Phase 2b data for Protagonist Therapeutics’ oral IL-23R inhibitor icotrokinra show strong efficacy and safety in ulcerative colitis; learn what’s next for Phase 3.
Johnson & Johnson (NYSE: JNJ) gains FDA approval to expand SIMPONI into pediatric ulcerative colitis
FDA approves SIMPONI (golimumab) for children ≥15 kg with ulcerative colitis, expanding Johnson & Johnson’s immunology portfolio. Learn what it means for patients.
Lilly’s Omvoh sets a new benchmark in ulcerative colitis with four-year steroid-free remission data
Eli Lilly’s Omvoh (mirikizumab-mrkz) delivers four years of steroid-free remission in ulcerative colitis patients according to LUCENT-3 data. Discover how this sets a new benchmark for IBD therapy.
Equillium secures financing to launch EQ504 Phase 1 trial in 2026
Equillium secures up to $50M to fund clinical entry of EQ504 mid-2026—discover how this financing shapes its immunology strategy.